Ignite Creation Date:
2024-05-11 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06400485
Status:
RECRUITING
Last Update Posted:
2024-05-23
First Post:
2024-05-01
Brief Title:
AMT-676 in Patients With Advanced Solid Tumors
Sponsor:
Multitude Therapeutics Inc
Organization:
Multitude Therapeutics Inc
Study Overview
Official Title:
First-in-Human Phase 1 Study of AMT-676 in Patients With Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a first-in-human non-randomized open-label multicenter Phase 1 study will evaluate the Maximum tolerated dose MTDthe recommended Phase 2 Dose RP2D safety tolerability anti-drug activity pharmacokinetics pharmacodynamics and immunogenicity of AMT-676 in Patients with Advanced Solid Tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None